LB Pharmaceuticals Presents LB-102 Cognitive Data LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized trials are the key catalyst.

LB Pharmaceuticals Presents LB-102 Cognitive Data: LB-102 cognitive data presented Mar 27, 2026 could affect ~20–30% of stroke survivors and 55M dementia patients globally; follow-on randomized… 👈 Read full analysis #LBPharmaceuticals #CognitiveData #DementiaResearch #StrokeSurvivors #ClinicalTrials